StockStory has named two high-flying stocks to watch and one to avoid, warning that expensive shares leave little room for error. It advises selling Inspire Medical Systems (NYSE:INSP), which makes an implantable device for obstructive sleep apnea. Revenue of $898.7 million is subscale, and it forecasts a 3.4% decline over the next 12 months. The shares trade at $69.10, or 52.2x forward earnings. Monolithic Power Systems (NASDAQ:MPWR), a power management chipmaker, grew revenue 27.6% a year over five years. Earnings per share rose 29.9% a year. Its $1,191 share price equals 35.9x forward earnings. Medpace (NASDAQ:MEDP), a clinical trial services provider, averaged 18.7% organic revenue growth over two years. It trades at $663.33, or 35.7x forward earnings.

Inspire Medical Systems (NYSE:INSP) stock price up 4% - here's what happened. Posted by ABMN Staff on Oct 12th, 2026 Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report)'s stock price shot up 4% on Monday. The company traded as high as $71.66 and last traded at $71.6680. 119,753 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 1,067,725 shares. The stock had previously closed at $68.89. Analysts set new price targets. INSP has been the topic of a number of analyst reports. Piper Sandler lifted their price target on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 4th. Evercore set a $54.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Weiss Ratings raised shares of Inspire Medical Systems from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, September 22nd. Barclays started coverage on shares of Inspire Medical Systems in a report on Tuesday, October 6th. They issued an "underweight" rating and a $65.00 target price for the company. Finally, Zacks Research downgraded shares of Inspire Medical Systems from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $67.29. Inspire Medical Systems price performance. Discover more Stock trading platform Stock market analysis Stock price tracker The company has a market cap of $2.08 billion, a PE ratio of 15.55, a price-to-earnings-growth ratio of 5.21 and a beta of 0.73. The stock has a fifty day moving average price of $65.23 and a 200-day moving average price of $54.18. Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. Inspire Medical Systems's revenue for the quarter was down 7.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year. Insiders place their bets. In other news, insider Jason Kelly sold 963 shares of the company's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is currently owned by company insiders. Institutional trading of Inspire Medical Systems. Several institutional investors have recently made changes to their positions in INSP. EverSource Wealth Advisors LLC raised its holdings in Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company's stock valued at $33,000 after acquiring an additional 580 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Inspire Medical Systems by 379.0% during the 2nd quarter. Versant Capital Management Inc now owns 958 shares of the company's stock worth $43,000 after purchasing an additional 758 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Inspire Medical Systems by 85.0% during the 2nd quarter. GAMMA Investing LLC now owns 1,221 shares of the company's stock worth $54,000 after purchasing an additional 561 shares in the last quarter. State of Wyoming grew its holdings in shares of Inspire Medical Systems by 83.7% during the 1st quarter. State of Wyoming now owns 1,343 shares of the company's stock worth $69,000 after purchasing an additional 612 shares in the last quarter. Finally, Nykredit A S bought a new stake in shares of Inspire Medical Systems during the second quarter valued at approximately $78,000. 94.91% of the stock is currently owned by institutional investors and hedge funds. About Inspire Medical Systems. Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company's primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy. The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead. Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.